722 Stock Overview
A biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Antengene Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.059 |
| 52 Week High | HK$0.24 |
| 52 Week Low | HK$0.059 |
| Beta | 0.85 |
| 11 Month Change | -37.23% |
| 3 Month Change | -32.18% |
| 1 Year Change | -60.93% |
| 33 Year Change | -97.11% |
| 5 Year Change | n/a |
| Change since IPO | -96.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 722 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.1% | -1.3% | 0.8% |
| 1Y | -60.9% | -17.7% | 6.1% |
Return vs Industry: 722 underperformed the German Pharmaceuticals industry which returned -17.7% over the past year.
Return vs Market: 722 underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| 722 volatility | |
|---|---|
| 722 Average Weekly Movement | 11.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 722's share price has been volatile over the past 3 months.
Volatility Over Time: 722's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 201 | Jay Mei | www.antengene.com |
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, Hong Kong, Macau, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR kinase inhibitor for the treatment of cervical cancer and other advanced solid tumors.
Antengene Corporation Limited Fundamentals Summary
| 722 fundamental statistics | |
|---|---|
| Market cap | €59.94m |
| Earnings (TTM) | -€73.95m |
| Revenue (TTM) | €8.56m |
7.0x
P/S Ratio-0.8x
P/E RatioIs 722 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 722 income statement (TTM) | |
|---|---|
| Revenue | CN¥67.31m |
| Cost of Revenue | CN¥12.29m |
| Gross Profit | CN¥55.01m |
| Other Expenses | CN¥636.20m |
| Earnings | -CN¥581.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 81.74% |
| Net Profit Margin | -863.51% |
| Debt/Equity Ratio | 15.7% |
How did 722 perform over the long term?
See historical performance and comparison